Abacus Life, Inc. (ABL)
$
7.73
+0.02 (0.26%)
Key metrics
Financial statements
Free cash flow per share
-2.2000
Market cap
837.6 Million
Price to sales ratio
6.1846
Debt to equity
0.2858
Current ratio
0.4699
Income quality
11.6894
Average inventory
0
ROE
-0.0525
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abacus Life, Inc. operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company reported selling, general, and administrative expenses of $90,797,902.00 indicating its operational overhead costs. Additionally, the company reported depreciation and amortization expenses of $7,910,158.00 reflecting the wear and tear of its assets. The cost of revenue for the company is $11,371,733.00 showcasing its production and operational expenses. The operating income ratio is 0.04 indicating the company's operational profitability margin. Moreover, the company's stock is identified with the symbol 'ABL' in the market, making it recognizable among investors. The firm was founded in 2004 and is based in Orlando, Florida. In the investment landscape, the stock is affordable at $7.71 suitable for budget-conscious investors. However, the stock has a low average trading volume of 401,920.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $739,114,772.00 the company is classified as a small-cap player. It is a key player in the Insurance - Life industry, contributing significantly to the overall market landscape, and it belongs to the Financial Services sector, driving innovation and growth. As such, Abacus Life, Inc. continues to navigate its niche within the financial markets, offering unique opportunities for those interested in its specialized products and services.
Is Abacus Life, Inc. (ABL) a good investment?
Investing in Abacus Life, Inc. (ABL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Abacus Life, Inc. (ABL)'s stock forecast?
Analysts predict Abacus Life, Inc. stock to fluctuate between $6.34 (low) and $12.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abacus Life, Inc.'s market capitalization?
As of 2025-05-30, Abacus Life, Inc.'s market cap is $739,114,772, based on 95,616,400 outstanding shares.
How does Abacus Life, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Abacus Life, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Abacus Life, Inc. (ABL) stock?
To buy Abacus Life, Inc. (ABL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABL. Place an order (Market, Limit, etc.).
What is the best time to invest in Abacus Life, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Abacus Life, Inc. perform in the last earnings report?
Revenue: $111,923,786 | EPS: -$0.32 | Growth: -288.24%.
Where can I find Abacus Life, Inc.'s investor relations reports?
Visit https://abacuslife.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abacus Life, Inc.?
You can explore historical data from here
What is the all-time high and low for Abacus Life, Inc. stock?
All-time high: $13.25 (2024-02-07) | All-time low: $5.47 (2023-07-19).
What are the key trends affecting Abacus Life, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
zacks.com
The consensus price target hints at a 57.5% upside potential for Abacus Life, Inc. (ABL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
Here is how Abacus Life, Inc. (ABL) and Annaly Capital Management (NLY) have performed compared to their sector so far this year.
seekingalpha.com
Abacus Global Management, Inc. (NASDAQ:ABL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Robert Phillips - Senior Vice President-Investor Relations & Corporate Affairs Jay Jackson - Chairman & Chief Executive Officer Bill McCauley - Chief Financial Officer Conference Call Participants Patrick Davitt - Autonomous Research Crispin Love - Piper Sandler Randy Binner - B. Riley Andrew Kligerman - TD Securities Mike Grondahl - Northland Securities Operator Greetings, and welcome to the Abacus Global Management First Quarter 2025 Earnings Call.
zacks.com
Abacus Life, Inc. (ABL) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.11 per share a year ago.
zacks.com
Investors need to pay close attention to ABL stock based on the movements in the options market lately.
prnewswire.com
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules a cross the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and near-term payments SEONGNAM, South Korea , April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as siRNA and ASOs, to address significant unmet medical needs of patients suffering from neurodegenerative conditions.
zacks.com
The mean of analysts' price targets for Abacus Life, Inc. (ABL) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
seekingalpha.com
Abacus Life, Inc. (NASDAQ:ABL ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Robert Phillips - SVP, IR and Corporate Affairs Jay Jackson - Chairman and CEO Bill McCauley - CFO Conference Call Participants Patrick Davitt - Autonomous Research Crispin Love - Piper Sandler Randy Binner - B. Riley Securities Mike Grondahl - Northland Securities Andrew Kligerman - TD Securities Operator Good day, ladies and gentlemen, and thank you for standing by.
prnewswire.com
HOUSTON , March 12, 2025 /PRNewswire/ -- KLX Energy Services Holdings, Inc. (Nasdaq: KLXE) ("KLX", the "Company", "we", "us" or "our") announced today that it has closed on refinancing its existing 2025 senior secured notes by issuing approximately $232 million of senior secured notes due March 2030 together with warrants to purchase common stock of the Company. The Company also announced it has closed on its new ABL credit facility due March 2028 with a $125 million commitment, a first-in-last-out facility with a $10 million commitment, and a committed incremental loan option with a $25 million commitment.
See all news
